Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Bausch (BHC) Suspends IPO Plans for Solta Medical
01:36pm, Friday, 17'th Jun 2022 Zacks Investment Research
Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
04:15pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
04:25pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.
Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug
04:23pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
10:13am, Monday, 13'th Jun 2022 Zacks Investment Research
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
03:57pm, Friday, 10'th Jun 2022 Zacks Investment Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMC
Has Geron (GERN) Outpaced Other Medical Stocks This Year?
01:40pm, Friday, 10'th Jun 2022 Zacks Investment Research
Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
01:33pm, Friday, 10'th Jun 2022
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMC
Has Geron (GERN) Outpaced Other Medical Stocks This Year?
11:17am, Friday, 10'th Jun 2022
Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
04:48pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
03:45pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
07:17pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah
07:10pm, Monday, 30'th May 2022 Zacks Investment Research
Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
07:03pm, Monday, 30'th May 2022 Zacks Investment Research
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
04:26pm, Monday, 23'rd May 2022 Zacks Investment Research
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
